Fibrosis Lessens After Metabolic Surgery
Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH); Liver Fibrosis; Obesity Interventions: Procedure: Metabolic surgery; Drug: Incretin-Based Therapy Sponsors: Ali Aminian Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat)
Conditions: Obesity; Diabetes Mellitus Type 2 in Obese Interventions: Behavioral: Weight loss-induced Diabetes Remission Sponsors: Azienda Ospedaliero, Universitaria Pisana Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
Conditions: Incretin Effect Interventions: Drug: GIP(1-42); Drug: GLP-1; Drug: GLP-2; Other: Placebo Sponsors: University of Copenhagen; Gentofte Hospital, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Incretin Effect in Patients With Psoriasis and Controls
Conditions: Psoriasis Vulgaris Interventions: Diagnostic Test: Oral glucose tolerance test; Other: Intravenous isoglycaemic glucose clamp; Other: Liquid Mixed meal test Sponsors: University Hospital, Gentofte, Copenhagen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials
Berberine on the Secretion of Incretin
Condition: Diabetes Mellitus Interventions: Drug: Berberine Chloride; Drug: Placebo Sponsor: Beijing Tongren Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 17, 2023 Category: Research Source Type: clinical trials
Evaluation of L-Cell Activity in the Small Intestine as Biliopancreatic Loop Extension in Obese Patients With DM2 Submitted to Roux-en-Y Gastric Bypass
Conditions: Severe Obesity; Type 2 Diabetes Mellitus in Obese Intervention: Other: Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells. Sponsor: University of Sao Paulo General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2022 Category: Research Source Type: clinical trials
